Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years

Published: 2025-05-14 07:57:08 ET BCRX

Published on 05/14/2025 at 07:57